The JAK2 V617F mutation, present in the majority of polycythemia vera (PV) patients, causes constitutive activation of JAK2 and seems to be responsible for the PV phenotype. However, the transcriptional changes triggered by the mutation have not yet been totally characterized. In this study, we performed a large-scale gene expression study using serial analysis of gene expression in bone marrow cells of a newly diagnosed PV patient harboring the JAK2 V617F mutation and in normal bone marrow cells of healthy donors. JUNB was one of the genes upregulated in PV, and we confirmed, by quantitative real-time PCR, an overexpression of JUNB in hematopoietic cells of other JAK2 V617F PV patients. Using Ba/F3-EPOR cell lines and primary human erythroblast cultures, we found that JUNB was transcriptionally induced after erythropoietin addition and that JAK2 V617F constitutively induced JunB protein expression. Furthermore, JUNB knockdown reduced not only the growth of Ba/F3 cells by inducing apoptosis, but also the clonogenic and proliferative potential of human erythroid progenitors. These results establish a role for JunB in normal erythropoiesis and indicate that JunB may play a major role in the development of JAK2 V617F myeloproliferative disorders.
Introduction
A unique, somatic mutation of JAK2 (JAK2 V617F) was recently described in patients with classical breakpoint cluster region/ abelson (BCR/ABL)-negative myeloproliferative disorders (MPDs). [1] [2] [3] [4] [5] [6] In vitro studies have demonstrated that the JAK2 V617F mutation leads to JAK2 autophosphorylation and constitutive activation of the downstream pathways janus kinase2-signal transducer and activator of transcription 5 (JAK2-STAT5), phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase/extracellular signal-regulated kinase-1 (MAPK/ERK). 1, 3, 4 In addition, the mutation induces cytokine hypersensitivity or growth factor independence in Ba/F3 cells. 1, 4, 7 In vivo, JAK2 V617F alone was able to induce different types of MPDs in retroviral or transgenic mouse models. 1, [8] [9] [10] [11] Thus, there is clear evidence that JAK2 V617F is a major molecular event in the development of polycythemia vera (PV), essential thrombocythemia and primitive myelofibrosis (PMF).
However, the actual molecular mechanisms triggered by JAK2 V617F that permit erythroid autonomous survival and proliferation remain incompletely understood. An interplay may exist between cell cycle regulation and apoptosis, and these processes are currently being investigated. The overexpression of B-cell leukemia xL (Bcl-xL), an inhibitor of apoptosis, correlates with in vitro survival of PV erythroblasts in the absence of erythropoietin (EPO), 12 and a sustained level of this protein alone is sufficient to induce endogenous erythroid colony (EEC) formation. 13 Moreover, JAK2-mutated erythroblasts display increased expression of short form of the FLICEinhibitory protein (c-FLIP short ) and resistance to death-receptorinduced apoptosis.
14 With regard to cell cycle, JAK2 V617F promotes G1/S-phase transition of Ba/F3-EPOR cells, through p27 downregulation 15 and cyclin D2 induction. 15, 16 Both apoptosis and the cell cycle are processes regulated by the transcription factor activator protein 1. 17, 18 Activator protein 1activity is modulated by a wide range of extracellular stimuli, including growth factors and cytokines, through MAPK cascades (ERK, JNK and p38), 19, 20 and the resulting transcription factor is composed by homo-or heterodimers of Jun, Fos and activating transcription factor (ATF) proteins. 19 The activator protein 1 JunB is encoded by an immediate response gene (JUNB gene), whose expression is rapidly stimulated by serum and hematopoietic growth factors [21] [22] [23] [24] [25] [26] Depending on the cellular background, both positive and negative roles have been described for JUNB in cell proliferation and survival. [27] [28] [29] [30] [31] [32] In turn, JunB seems to regulate genes involved in cell cycle progression and apoptosis, such as p16, 33 p27, 25 cyclin D1, 34 cyclin A 35 and Bcl-xL. 36 In this study, we observed an overexpression of JUNB mRNA in the bone marrow cells of a JAK2 V617F-positive PV patient, by means of serial analysis of gene expression (SAGE) libraries and studied the role of JUNB in normal and JAK2 V617F-driven erythropoiesis.
Materials and methods

Patients
Peripheral blood or bone marrow samples were collected from PV and PMF patients. Only JAK2 V617F-positive patients were studied. As controls, bone marrow and peripheral blood samples were collected from healthy donors and patients undergoing cytapheresis. The study was approved by the Local Research Ethics Committee of the Hôtel-Dieu and the Henri Mondor hospitals (France) and the Faculty of Medical Sciences, State University of Campinas (Brazil). Informed consent was obtained from each patient, in accordance with the Declaration of Helsinki.
Cell preparation
The bulk of bone marrow cells was recovered by centrifugation, after red blood cell lysis. Similarly, total cells were obtained from peripheral blood samples. Granulocytes and mononuclear cells were separated using a double gradient of HISTOPAQUE-1119 and HISTOPAQUE-1077 (Sigma-Aldrich, Steinheim, Germany).
Purification of CD34
þ cells and in vitro amplification of erythroid progenitors Mononuclear cells were obtained over a Ficoll density gradient and CD34 þ cells were purified by a double-positive magnetic cell sorting system (AutoMACS, Miltenyi Biotec, Paris, France). CD34 þ cells were cultured in a liquid culture system stimulating erythropoiesis, in the presence of 50 ng/ml recombinant human stem cell factor (Amgen, Thousand Oaks, CA, USA), 50 U/ml interleukin-3 (Novartis, Basel, Switzerland) and 1 U/ml EPO (Orthobiotech, Paris, France), as described previously, 37 supplemented with 10% fetal bovine serum (FBS) (Stem Cell Technologies, Meylan, France) until day 7 and 30% FBS from day 7 to day 13.
Cell lines
Parental, JAK2 WT-or JAK2 V617F-expressing Ba/F3-EPOR cells 1 were cultured in Roswell Park Memorial Institute (RPMI) medium (Invitrogen, Cergy Pontoise, France) complemented with 10% FBS and in the presence of 1 U/ml EPO. JAK2 V617F-expressing UKE-1 cells 38, 39 were cultured in RPMI medium supplemented with 10% FBS, 10% horse serum and 1 mM hydrocortisone. The inhibitors AG490, JAK2 inhibitor II and lactacystin were purchased from Calbiochem (VWR, Fontenay sous Bois, France), and AZD1480 was a generous gift from AstraZeneca (Waltham, MA, USA).
shRNA constructs, lentivirus production and cell infection
To down-modulate JUNB expression, lentivirus-mediated short hairpins RNAs were used, and lentiviral particles were prepared as described previously. 40 Erythroid precursor cells, cultured during 4 days as described above, were incubated with the viral supernatant for 24 h. On day 5, GFP þ /CD36 þ /Gpa À cells were sorted after immunostaining with specific antibodies (Immunotech, Marseille Luminy, France) with a cell sorter (FACSDiva, Becton Dickinson, Le Pont de Claix, France). Lentivirusmediated short hairpin RNAs were also used to down-modulate JUNB or JAK2 V617F (Jedidi et al., submitted) 41 expression in parental, JAK2 WT-or JAK2 V617F-expressing Ba/F3-EPOR cells.
Proliferation and erythroid progenitor assays
For the erythroid progenitor proliferation assay, 18 000 GFP þ / CD36 þ /Gpa À cells were cultured in the liquid system described above. For the colony assay, 1000 GFP þ /CD36 þ /Gpa À cells were plated in duplicate in semisolid methylcellulose H4100 Medium (Stem Cell Technologies) supplemented with 10% FBS, 25 ng/ml stem cell factor and 3 U/ml EPO, as described. 13 Erythroid colonies were plucked from methylcellulose and the mutational status was analyzed by quantitative real-time PCR (qRT-PCR), using fluorescent competitive probes. Additionally, for JAK2 V617-positive patients, 5000 GFP þ /CD36 þ /Gpa À cells were plated in the absence of EPO. For the Ba/F3-EPOR proliferation assay, 10 000 cells were cultured in RPMI medium complemented with 10% FBS in the presence or absence of 0.1 or 1 U/ml EPO.
Apoptosis assay
Cells were incubated with Annexin V-APC, which is able to detect the translocated membrane phospholipid phosphatidylserine, and then were incubated with the vital dye 7-Amino Actinomycin D (7-AAD). Annexin V þ (corresponding to early apoptosis) and Annexin V þ /7AAD þ (corresponding to late apoptosis) cells were detected by fluorescence-activated cell sorting (FACS) analysis, according to the manufacturer's recommendations (BD Pharmingen, Franklin Lakes, NJ, USA). 
SAGE libraries and data analysis
The PV library (SAGE PV) was produced from mRNA obtained from bone marrow cells of a single JAK2 V617F-positive PV patient, at the time of diagnosis. The control library (SAGE CT) was generated from a pool of RNA obtained from bone marrow cells of five donors. Libraries were constructed using the I-SAGE kit (Invitrogen) with the NlaIII enzyme, as described by the manufacturer. The SAGE PV library was compared with the control SAGE CT library and to a normal bone marrow library available at the NCBI SAGE website. Only tags presenting Po0.05 42 and fold X5 in the two comparisons were considered to be differently expressed.
Quantitative real-time PCR
Quantitative real-time PCR was performed in duplicate, using the SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA) and specific primers (Supplementary Table 1 ). To validate SAGE profiles, low-and high-expression genes were analyzed. Therefore, BAC, GAPDH and BCR were used as reference genes, and gene expression was normalized using the Program geNorm, version 3.4. 43 To analyze JUNB expression, GAPDH was used as reference gene and fold increase was calculated by the conventional DDC t method.
Western blotting
Western blotting was performed using anti-JunB (C-11) sc-8051 (Santa Cruz, TEBU, Le Perray en Yvelines, France), anti-phospho STAT5, anti-STAT5, anti-phospho thr308 protein kinase B (AKT/PBK), anti-AKT, anti-phospho ERK p42-p44, anti-ERK p42-p44, anti-JAK2 (Cell Signaling, Saint Quentin en Yvelines, France) or anti-b-actin (Sigma, Saint-Quentin Fallavier, France) antibodies, according to conventional techniques. Each experiment was repeated three times and representative blots are shown. Quantifications were performed using ImageJ software 1.37v.
Statistical analysis
Results are presented as mean±s.d. Mann-Whitney test was applied to analyze differences in JUNB gene expression between groups of PV patients and controls. In the apoptosis and cell viability assays, Student's t-test was used. Po0.05 was considered as significant.
Results
Gene expression profiles of normal and PV bone marrow cells
We performed a large-scale gene expression study in normal and PV bone marrow cells, using SAGE. A total of 68 584 tags for the SAGE PV profile and 58 401 tags for the SAGE CT profile were sequenced, representing 21 042 and 18 926 unique tags, respectively. The full tables of tags are available on the site http://www.lge.ibi.unicamp.br/~anderf. To investigate the reliability of the profiles designed by SAGE, we arbitrarily selected 11 genes to be studied by qRT-PCR in the PV sample used to generate the library and in three of the five control samples. Both techniques were consistent in identifying higher expression of HBA, HBB, C3orf10, PRDX6, GPR137B, JUNB, ZFP36, BTG2 and EGR1 in PV, and C1QB and AHSP in the normal samples (Supplementary Figure 1) .
We identified 70 tags (60 different transcripts) that were downregulated in PV bone marrow cells, whereas 136 tags (104 different transcripts) were overexpressed. Genes upregulated in PV were associated with many biological processes known to be altered in the disease (Supplementary Table 2 ), such as signal transduction, cell cycle, apoptosis and regulation of transcription.
JUNB expression in hematopoietic cells
One of the genes implicated in the regulation of transcription identified was JUNB, which codes for a member of the activator protein 1 transcription complex. As it has been reported that JAK2 activation may contribute to JUNB induction, 44 the pattern of JUNB expression in hematopoietic cells was investigated in other JAK2 V617F-positive PV patients (Figure 1 ). We found an overexpression of JUNB mRNA in bone marrow cells of two newly diagnosed PV patients (Figure 1a ). In addition, PV peripheral blood leukocytes displayed higher JUNB mRNA levels than normal leukocytes (six PV patients and six healthy donors, Mann-Whitney, Po0.01) (Figure 1b) . JUNB expression was shown to be twofold greater in PV mononuclear cells (monocytes þ lymphocytes) than normal counterparts (13 PV patients and 14 controls, Mann-Whitney, Po0.05) (Figure 1c) . However, surprisingly, no significant differences were found for granulocytes between control and JAK2 V617F-positive samples (14 PV patients and 14 controls, Mann-Whitney, P40.05) (Figure 1d ).
JAK2 V617F-expressing Ba/F3-EPOR cells show constitutive expression of JunB
The differences observed between JAK2 V617F-positive PV patients and controls suggest that JUNB expression may depend upon JAK2 status. In fact, JAK2 V617F-expressing Ba/F3-EPOR cells showed greater JunB protein levels than parental or JAK2 WT-expressing cells, as detected by western blot (Figure 2a) . After 6 h of cytokine and serum deprivation, JunB expression decreased in both parental and JAK2 WT-expressing cells, whereas in JAK2-mutated cells, it remained detectable (Figure 2a) . We also observed that, in steady state or in deprivation, JUNB mRNA levels were greater in JAK2 V617F-expressing cells than in parental or JAK2 WT-expressing Ba/F3-EPOR cells and that EPO stimulation increased JUNB mRNA levels in the three cell lines (Supplementary Figures 2a and b) . Moreover, when cells were treated with 10 mM lactacystin (an inhibitor of proteasome) for 6 h under deprivation conditions, JunB protein levels were increased. These results show that under deprivation conditions, JunB protein levels were downregulated not only by reducing JUNB mRNA levels, but also by proteasome degradation of the protein (Supplementary Figures  2a and c) .
JunB expression is dependent on JAK2 V617F in JAK2 V617F cell lines
To further investigate the relationship between JunB expression and the mutation, JAK2 inhibitors (AG490, JAK2 inhibitor II or AZD1480) or an shRNA targeting specifically JAK2 V617F were used. In JAK2 V617F-expressing Ba/F3-EPOR cells, the basal JunB levels were reduced by nearly 50% by AG490 at a concentration of 25 mM. Decreased levels of JunB were also observed in the presence of AZD1480 and JAK2 inhibitor II (Figure 2b) . Similarly, in the JAK2 V617F-expressing cell line UKE-1, AG490 also diminished JunB protein levels (Figure 2b ). STAT5 phosphorylation status was used as a surrogate marker to test the efficiency of JAK2 inhibitors (Figure 2b ). Two inhibitors, AG490 and AZD1480, markedly decreased P-STAT5, whereas JAK2 inhibitor II had a slight effect. In addition, the shRNA used to down-modulate JAK2 V617F expression in JAK2 V617F-expressing Ba/F3-EPOR cells caused a decrease in JunB protein levels, both in steady state and in deprivation conditions (Figure 2b) . Altogether, these results showed that JunB expression depends on JAK2 V617F activity.
The two major pathways triggered by JAK2 activation and shown to be constitutively active in mutated cells are the PI3K/ AKT and the MEK/ERK pathways. 1 We then investigated whether these pathways are involved in JunB expression, by using LY294002, a PI3K inhibitor, or PD98059, an MEK inhibitor. Increasing concentrations of LY294002 or PD98059 lowered JunB protein levels (Figures 2c and d) . Thus, both pathways seem to contribute to JunB expression in JAK2-mutated cells. STAT5 activation may play a minor role in the regulation of JunB expression, as suggested by the fact that JAK2 inhibitor II decreases markedly JunB expression, whereas having a moderate effect on STAT5 phosphorylation (Figure 2b ).
JunB is constitutively expressed in erythroid precursor cells of JAK2 V617F-positive patients
Then, we extended these results to primary erythroid precursor cells. Erythroid cells were obtained from CD34 þ progenitors cultured for 7 or 10 days in a liquid culture system (Figure 3a) , and JunB protein expression was analyzed in steady-state condition (10% FBS, 50 ng/ml stem cell factor, 1 U/ml interleukin-3, 1 U/ml EPO), 4 h after deprivation (no FCS, no cytokine) and 3 h after EPO re-stimulation (10 U/ml) (Figure 3b ). STAT5 phosphorylation was assessed to verify the efficiency of EPO restimulation. Three controls and four patients (three PV patients and one PMF patient) were analyzed for JunB expression. Figure 3b illustrates the results for two controls and three patients. Erythroid precursors derived from controls showed a decrease in JunB protein levels due to EPO withdrawal, whereas cells from the JAK2 V617F-positive patients maintained JunB protein levels even after EPO deprivation. These results demonstrate that a constitutive expression of JunB is observed in JAK2 V617F erythroid precursors in contrast to normal erythroid progenitors.
JUNB knockdown diminishes the proliferation of Ba/F3-EPOR cells and human erythroid precursor cells
In a first approach to study the function of JunB, lentivirus vectors containing shRNA targeted on JUNB were used in Ba/F3-EPOR cells. Both shJUNB1 (murine specific) and shJUNB3 were able to inhibit JunB expression, as observed by western blotting, in the parental, JAK2 WT-and JAK2 V617F-expressing cell lines (Figure 4a, inset) . JUNB knockdown led to a lower proliferation of all three cell lines (Figure 4a ) in the presence of EPO. In addition, EPO-independent cell growth was also reduced in JAK2 V617F-expressing Ba/F3-EPOR cells transduced with shJUNB1 or shJUNB3, compared with shSCR ( Figure 4b) . Finally, JUNB knockdown did not modify cell cycle distribution (data not shown) but rather induced an increase in apoptotic cells, as detected by FACS analysis using the Annexin V/7-AAD labeling (Figure 4c) .
To estimate the role of JunB in erythropoiesis, day 4 erythroid precursors were infected with a lentivirus vector containing shRNA targeted on JUNB and GFP. GFP þ /CD36 þ /Gpa À cells transduced with shJUNB or shSCR were sorted. As shown in Figure 5a , transduction with shJUNB1 and shJUNB3 resulted in a decrease in JunB levels, as confirmed by western blotting. Levels of JunB inhibition were similar among the different samples, but shJUNB3 was more efficient than shJUNB2 (human specific) in diminishing JunB protein levels.
In the proliferation assay, shJUNB3 reduced cell growth in comparison with shSCR, both for controls and patients, whereas shJUNB2 had only a marginal effect (Figure 5b) . Decreased cell growth caused by shJUNB3 correlated with a significant increase in the proportion of apoptotic cells (Figure 5c ).
Erythroid colony formation was studied by plating GFP þ / CD36 þ /Gpa À cells in methylcellulose, in the presence of EPO. shJUNB3 significantly inhibited the growth of erythroid colonies, both for controls and patients (Figure 5d ). In contrast, shJUNB2 diminished the clonogenic potential of the three PV patients studied, but induced only a nonsignificant decrease in the PMF patients. Moreover, we observed that JUNB knockdown with either shJUNB2 or shJUNB3 led to a reduction in colony size (Figure 5e ). The JAK2 status of colonies growing after shSCR or shJUNB (shJUNB2 or shJUNB3) transduction was then investigated in six patients. In patients PV1, PV4 and PMF2, who presented not only JAK2 V617F homozygous progenitors, but also heterozygous and/or normal progenitors, JUNB downregulation led to a marked reduction in the proportion of colonies derived from homozygous progenitors (Figure 5f ). In contrast, in patients presenting only (PV2) or no (PV3 and PMF1) homozygous colonies, no significant effect of shJUNB on the proportion of growing colonies was observed. This may be explained in PV2 by an almost absence of normal clones. To confirm this result, we studied the effect of shJUNB3 on EEC formation, which mainly arises from homozygous JAK2 V617F erythroid progenitors. shSCR-or shJUNB3-transduced GFP þ / CD36 þ /Gpa À cells from 3 JAK2 V617F-positive patients were plated in methylcellulose, in the absence of EPO. As illustrated in Figure 5g , shJUNB3 elicited a significant reduction in EEC formation. This last result shows that the JAK2 V617F erythroid progenitors are very sensitive to JunB downregulation in the absence of EPO.
Discussion
In this study, we performed a SAGE in normal and JAK2 V617F-positive bone marrow cells and identified several genes, the expressions of which are modulated in PV, including JUNB. Of the genes regulated by JUNB, we observed, by SAGE, that p16, cyclin A and cyclin D1 are expressed at low level and are not differently regulated between the libraries. We were able to confirm JUNB overexpression in bone marrow cells of two other newly diagnosed JAK2 V617F-positive PV patients. JUNB upregulation was also observed in total peripheral blood leukocytes and mononuclear cells of mutated PV patients, compared with controls. These results suggested that JUNB expression could be related to the JAK2 genotype. Although a previous study did not highlight JUNB as an upregulated gene in CD34 þ cells from PMF patients using oligonucleotide microarray, 45 another group detected an enhanced expression of JUNB, 46 in line with our data. However, no significant differences in JUNB levels were recorded between normal and PV mature granulocytes, although they derive from the mutated clone in PV. Previous global expression analysis of MPD granulocytes did not highlight changes in JUNB expression either. [47] [48] [49] It may be speculated that variations in JUNB expression in the hematopoietic lineages may depend on the cellular background.
In agreement with this overexpression of JUNB in the bone marrow, we found that JAK2 V617F Ba/F3-EPOR cells, as well as primary erythroid cells of JAK2 V617F-positive PV and PMF patients, display EPO-independent JunB expression. These results are in line with the EPO-independent JUNB expression in HCD-57 cells infected with the Friend spleen focus-forming virus, 50 which induces erythroid cell growth in the absence of EPO, 51 similar to the JAK2 mutation.
Taken together, these observations suggest, for the first time, that JunB is regulated by JAK2 V617F. This was confirmed by the decrease in JunB expression after treatment of JAK2 V617F cells with JAK2 inhibitors or an shRNA targeting specifically JAK2 V617F (Jedidi et al., submitted). Using inhibitors (LY294002 and PD98059), we were also able to show that JunB constitutive expression in JAK2 V617F cells was dependent on the PI3K and MAPK pathways. This is in agreement with the results obtained with another constitutively active kinase, nucleophosmin/anaplastic lymphoma kinase (NPM-ALK), which increases JUNB mRNA and JunB protein levels through the activation of ERK and PI3K. 27 Given these results, we next addressed the role of JUNB in the erythropoiesis. With regard to the functions of JUNB in hematopoiesis, it has been shown that this transcription factor plays a key role in the early steps of the myelopoiesis, as JUNB deficiency leads to a transplantable MPD, by expanding the numbers of long-term hematopoietic stem cells and granulocyte/ macrophage progenitors. 52 To more precisely understand the role of JunB in erythropoiesis, we used a knockdown strategy using shRNAs. JUNB down-modulation caused a decrease in the proliferation and clonogenic potential of erythroid precursors and raised the percentage of apoptotic cells, suggesting a major role for JunB in the erythropoiesis. In line with these findings, JUNB down-modulation also decreased proliferation in Ba/F3 cell lines. Thus, this result markedly differs from a previous report suggesting that JunB was responsible for the apoptosis induced by EPO withdrawal and that, in contrast, c-Jun was involved in the EPO-induced proliferation of the erythroid cell line, HCD57. 36 However, the opposing role of these two jun proteins was hypothesized only for their expression during EPO stimulation, but not for their precise function. JAK2 V617F erythropoiesis was more sensitive to the downregulation of JUNB; indeed, EEC formation was nearly completely blocked by JunB knockdown. When the genotypes of the EPO-stimulated erythroid colonies were studied after JUNB inhibition, a decrease in JAK2 V617F homozygous colonies was observed. This may imply that activation of JunB is an important molecular mechanism for JAK2 V617F-driven erythropoiesis.
Conclusion
These results highlight the totally opposite effects of one key molecule at different stages of hematopoiesis. JUNB deficiency in hematopoietic stem cells induces an MPD resembling chronic myeloid leukemia, by expanding the number of hematopoietic stem cells and inducing the proliferation of granulocytic precursors. In contrast, JUNB knockdown in granulomonocytic progenitors and precursors has only a minimum effect on their proliferation. In erythropoiesis, JunB is an important molecule downstream of the EPO-R and, in vitro, appears indispensable for JAK2 V617F-driven erythropoiesis. Future investigations of JunB in JAK2 V617F MPD should permit the determination of its precise role in the pathogenesis of these disorders. 
